Abstract 5983
Background
Immunotherapy represents a new standard of care in first and second line treatment of advanced NSCLC. Immune related adverse events (irAEs) have been proposed as an indicator of treatment efficacy.
Methods
Retrospective analysis of mNSCLC patients treated with anti-PD/anti-PDL1 with or without anti-CTLA4 therapy. Electronic patient records were reviewed; irAEs were identified and graded according to CTC AE v4.03 criteria. The association with survival was evaluated in uni- (UV) and multivariable (MV) Cox-regression models.
Results
64 pts were identified; 41 (64.1%) were adenocarcinomas and 27 (42.2%) received immunotherapy in first-line. 44 pts (68.8%) received antiPD1/PDL1 monotherapy, and 20 pts (31.2%) received antiPDL1 + antiCTLA4. 15 pts (25%) developed irAEs: gastrointestinal (17.6%), endocrine (11.8%), cutaneous (17.6%), other (33.3%). Treatment was interrupted in 8 (53.3%) and suspended in 5 (33.3%) pts. 7 (50%) pts received high dose corticosteroids. No toxic deaths occurred. iRAEs were not significantly increased in pts receiving combination therapy (30% vs 20%, p = 0.377). Median OS was 6.5 m (95%CI: 0.24-12.7). Pts experiencing irAEs had a significantly higher OS (HR: 0.2; 95%CI: 0.07-0.58; p = 0.003) in UV analysis, and was independent of other prognostic factors in MV analysis (Table).Table: 1391P MV Cox-regression survival model
| Factor | HR (95%CI) | p-value |
|---|---|---|
| irAE (yes vs no) | 0.18 (0.06 – 0.53) | 0.002 |
| Histology | 1.11 (0.99 – 1.24) | 0.061 |
| ECOG PS | 0.82 (0.42 – 1.59) | 0.551 |
| Treatment line (first line vs second or further) | 1.06 (0.52 – 2.18) | 0.868 |
| Treatment type (monotherapy vs combination) | 2.25 (1.02 – 4.99) | 0.045 |
Conclusions
The development of irAEs may identify pts with a higher likelihood of benefitting from immunotherapy in NSCLC. These findings will require prospective validation in well-designed clinical trials.
Clinical trial identification
Legal entity responsible for the study
Instituto Investigación Sanitaria La Fe.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4293 - Prediction of response to vemurafenib in BRAF V600E mutant cancers based on a network approach
Presenter: Rosa Falcone
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4384 - Improving value for cancer patients: A European study of outcomes in practice
Presenter: Rishi Hazarika
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5485 - High-throughput screening of new drugs targeting lung CSCs
Presenter: Héctor Amado Labrador
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4218 - RING observational trial to compare T790M mutation testing in blood by different methodologies
Presenter: Beatriz Garcia-Pelaez
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2775 - Indicators of non-participation in cervical cancer screening: Results from the EDIFICE 6 survey
Presenter: Thibault de La Motte Rouge
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5852 - Tolerance and efficacy of immune-checkpoint inhibitors for cancer in people living with HIV (PWHIV)
Presenter: Aurélien Gobert
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
819 - Effects of physical exercise in non-operable lung cancer patients undergoing palliative treatment
Presenter: Joachim Wiskemann
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract